Celltrion’s CT-P71 receives FDA Fast Track designation for urothelial cancer
Celltrion said CT-P71 received FDA Fast Track designation for previously treated locally advanced or metastatic urothelial cancer. The ADC candidate is in Phase 1 testing.
Urothelial Cancer
DiseaseRelated News
IDEAYA Biosciences Reports Q4 2025 Results, Awaits Pivotal Uveal Melanoma Trial Data
IDEAYA Biosciences announced Q4 2025 financial results with $1.05 billion in cash reserves and confirmed 130 progression-free survival events in its Phase 2/3 OptimUM-02 trial of darovasertib for metastatic uveal melanoma, with topline results expected by late March 2026.
Two Biotech Companies Report 2025 Financial Results and Pipeline Progress
Edgewise Therapeutics and IDEAYA Biosciences released annual financial reports detailing clinical trial progress and strategic initiatives. Both companies are advancing multiple clinical-stage programs while managing significant operating expenses.
Related Clinical Trials
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07768358 |
Tucatinib Continuation Study |
NOT_YET_RECRUITING | PHASE4 |
| NCT07566156 |
Enfortumab Vedotin in Combination With Pembrolizumab vs. Concurrent Chemoradiotherapy (cCRT) in People With Muscle Invasive Bladder Cancer (EV-309) |
RECRUITING | PHASE3 |
| NCT07548476 |
Acupuncture and Exercise for EV-Pembro-Induced Peripheral Neuropathy |
RECRUITING | NA |
| NCT07545122 |
A Phase 1a/1b, First-Time-in-Human Study of CT-202, a Nectin-4 Directed Bispecific Antibody, in Participants With Recurring Triple Negative Breast, Colorectal, Urothelial Cancers |
RECRUITING | PHASE1 |
| NCT07421700 |
Symbiotic-GU-06: A Study to Learn About PF-08634404 Alone or In Combination With Enfortumab Vedotin in Urothelial Cancer |
RECRUITING | PHASE1/PHASE2 |
| NCT07420855 |
International Multicentric Retrospective Study on the Use of EV+P as First-line Therapy in Patients With la/mUC |
NOT_YET_RECRUITING | |
| NCT07413120 |
Efficacy and Safety of VasoClip® vs. WeckClip® for Robotic Urologic Surgery |
COMPLETED | PHASE3 |
| NCT07386847 |
A Real-world Study of the First Treatment and Outcomes of Patients With Advanced or Metastatic Bladder Cancer |
COMPLETED | |
| NCT07227168 |
A Study of STRO-004 in Adults With Refractory/Recurrent Metastatic Cancer |
RECRUITING | PHASE1 |
| NCT07217496 |
N-803 in Combination With Pembrolizumab and Enfortumab Vedotin for Treatment of Urothelial Cancer |
WITHDRAWN | PHASE1 |